amikacin
Antiinfectives for systemic use (J01)Antiinfectives for systemic use (J01) compound in Pacira Ireland's portfolio.
pharma · Postoperative Pain · Pain · PCRX
Pacira Ireland
Pacira Ireland Limited
Pacira Ireland drug portfolio — 32 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Ranelagh, IE HQ
2007 Founded
7 Employees
Public company Type
PCRX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Ranelagh, IE
- Founded
- 2007
- Employees
- 7
- Programs
- 100
- Drugs
- 32
- Patents
- 57
Pacira Ireland pipeline
Portfolio lens on 32 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Pacira Ireland drug portfolio — 32 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Beta-2 adrenergic receptor.
- Target
- Beta-2 adrenergic receptor
- Mechanism
- Beta-2 adrenergic receptor agonist
-
Development asset linked to Pacira Ireland in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Molecular target: GABA-B receptor.
- Target
- GABA-B receptor
- Mechanism
- GABA-B receptor agonist
-
bupivacaine
Nervous system (N01)US regulatory status: approved. Molecular target: Sodium channel protein type 4 subunit alpha.
- Target
- Sodium channel protein type 4 subunit alpha
- Mechanism
- Sodium channel protein type IV alpha subunit blocker
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
cytarabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
duloxetine
Nervous system (N06)Nervous system (N06) compound in Pacira Ireland's portfolio. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Norepinephrine transporter inhibitor
-
Development asset linked to Pacira Ireland in public FDA and regional records.
-
formoterol
Respiratory system (R03)Respiratory system (R03) compound in Pacira Ireland's portfolio. Mechanism: Beta-2 adrenergic receptor agonist.
- Mechanism
- Beta-2 adrenergic receptor agonist
-
Development asset linked to Pacira Ireland in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
-
Development asset linked to Pacira Ireland in public FDA and regional records.
-
Development asset linked to Pacira Ireland in public FDA and regional records.
-
Development asset linked to Pacira Ireland in public FDA and regional records.
-
Development asset linked to Pacira Ireland in public FDA and regional records.
-
Development asset linked to Pacira Ireland in public FDA and regional records.
-
Development asset linked to Pacira Ireland in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist
-
US regulatory status: approved. Molecular target: Mu-type opioid receptor.
- Target
- Mu-type opioid receptor
- Mechanism
- Mu opioid receptor agonist
-
Development asset linked to Pacira Ireland in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist
-
US regulatory status: approved. Molecular target: Mu-type opioid receptor.
- Target
- Mu-type opioid receptor
- Mechanism
- Mu opioid receptor agonist
-
Development asset linked to Pacira Ireland in public FDA and regional records.
-
Development asset linked to Pacira Ireland in public FDA and regional records.
-
Development asset linked to Pacira Ireland in public FDA and regional records.
-
Development asset linked to Pacira Ireland in public FDA and regional records.
-
Development asset linked to Pacira Ireland in public FDA and regional records.
-
Development asset linked to Pacira Ireland in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist